SCHEMBL26869341

SCHEMBL26869341

Cn1nc2ccc(OCc3ccccc3F)cc2c1C(=O)NC(CO)CO

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP15 Q460N3 3/20 0.42
PARP10 Q53GL7 3/20 0.42
PTPN1 P18031 6/20 0.42
PTPN2 P17706 4/20 0.42
CDC25B P30305 4/20 0.42
MAOB P27338 3/20 0.42
ACSS2 Q9NR19 1/20 0.41
SCN9A Q15858 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
KCNH2 Q12809 2/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PARP14 Q460N5 1/20 0.39
PTPN6 P29350 1/20 0.39
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714741 0.87 SCN9A (0.52) PARP15PARP10PTPN1PTPN2CDC25B
SCHEMBL30714667 0.87 SCN9A (0.52) PARP15PARP10PTPN1PTPN2CDC25B
SCHEMBL26696061 0.84 PARP10 (0.47) PARP15PARP10PTPN1PTPN2CDC25B
SCHEMBL26696059 0.84 PARP15 (0.48) PARP15PARP10PTPN1MAOBSCN9A
SCHEMBL26869339 0.84 SMO (0.42) PARP10KCNH2NFKB1
SCHEMBL30714696 0.84 SMO (0.42) PARP10KCNH2NFKB1
SCHEMBL31539874 0.83 PARP10 (0.54) PARP15PARP10PTPN1MAOBSCN9A
SCHEMBL30714628 0.83 PARP15 (0.40) PARP15PARP10PTPN1PTPN2CDC25B
SCHEMBL26868370 0.82 GUCY1B2 (0.38) PARP15PARP10PTPN1PTPN2CDC25B
SCHEMBL30714556 0.81 PARP15 (0.42) PARP15PARP10PTPN1MAOBSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 PARP15 1331/4885PARP10 1863/4885PTPN1 3963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.